Innovative Cellular trims Lyell Immunopharma (LYEL) stake with small share sale
Rhea-AI Filing Summary
Innovative Cellular Therapeutics Holdings Ltd, a 10% owner of Lyell Immunopharma, Inc., reported a sale of 10 shares of Lyell common stock on 2026-07-16 at $13.73 per share. The trade was made pursuant to a Rule 10b5-1 trading plan, leaving the holder with 2,857,490 common shares afterward, down from 2,857,500 immediately before the sale.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 10 shares ($137)
Net Sell
1 txn
Insider
Innovative Cellular Therapeutics Holdings Ltd
Role
10% Owner
Sold
10 shs ($137.30)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 10 | $13.73 | $137.30 |
Holdings After Transaction:
Common Stock — 2,857,490 shares (Direct)
Footnotes (1)
- [object Object]
Key Figures
Shares sold: 10 shares
Sale price: $13.73 per share
Post-transaction holdings: 2,857,490 shares
+1 more
4 metrics
Shares sold
10 shares
Non-derivative sale of Lyell common stock on 2026-07-16
Sale price
$13.73 per share
Price received for each share sold on 2026-07-16
Post-transaction holdings
2,857,490 shares
Lyell common shares beneficially owned after the sale
Pre-transaction holdings
2,857,500 shares
Lyell common shares beneficially owned immediately before the sale
Key Terms
beneficially owned, Common Stock
2 terms
beneficially owned financial
"Reflects 2,857,500 shares of Common Stock beneficially owned by the Reporting Person"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
Common Stock financial
"Reflects 2,857,500 shares of Common Stock beneficially owned by the Reporting Person"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Innovative Cellular report in Lyell (LYEL)?
Innovative Cellular Therapeutics Holdings Ltd reported a sale of 10 Lyell Immunopharma common shares on 2026-07-16. This was a routine Form 4 disclosure of a small change in its beneficial ownership position in Lyell.
What are Innovative Cellular’s remaining LYEL holdings after this sale?
After the sale, Innovative Cellular beneficially owns 2,857,490 Lyell shares. A footnote explains that it held 2,857,500 shares immediately before the transaction, and the 10 shares sold reduced its position to the reported post-transaction balance.
What type of security was involved in this LYEL insider transaction?
The transaction involved Common Stock of Lyell Immunopharma, Inc. It is classified as a non-derivative security, meaning it was a direct trade in shares rather than through options, warrants, or other derivative instruments.